Safe Psilocybin

Scientists have proven the safety of long-term psilocybin intake

Svetlana Maslova, Hi-tech+

Scientists conducted a new experiment as part of clinical studies of psilocybin for the treatment of depression and post-traumatic stress disorder. Since the substance has repeatedly shown an advantage over antidepressants, the conclusions about the safety of treatment open up great hopes for the appearance of a simple and effective treatment in the future.

Scientists from King's College London found that the administration of psilocybin in dosages of 10 and 25 mg is safe for humans and does not lead to any changes in cognitive functions and the emotional sphere. The follow-up was an early part of the psilocybin-based therapy clinical development program for people with resistant depression and post-traumatic stress disorder.

The study involved 60 healthy people in the psilocybin group and 29 people in the control group. In both cases, the volunteers were provided with psychological support. The observations lasted for 12 weeks with an active period on the first day after administration.

Throughout the experiment, none of the volunteers dropped out due to any adverse health event or signs of stable trends. Scientists strictly evaluated various changes in the function of attention, memory, planning, emotion processing and other criteria.

The obtained results have become a solid basis for clinical studies of depression and PTSD, the third phase of which should be completed at the end of 2022.

The press release of Psilocybin, in 10mg or 25mg doses, has no short- or long-term detrimental effects in healthy people published on the college website, article by Rucker et al. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomized, placebo-controlled trial involving simultaneous psilocybin administration and preparation – in Journal of Psychopharmacology – VM.

Portal "Eternal youth" http://vechnayamolodost.ru